Guidelines include a high Ki67 level as an indicator for increased risk of recurrence in patients who have estrogen receptor positive, HER-2-receptor negative bract cancer patients, this may indirectly support the need for the modification of the endocrine and the chemotherapy regimen in such patients [10]. This evidence concerns the gene MKI67 and cancer.